Strategic services to help clients meet the challenges of treating cancer in the 21st century


Berkeley Heights, NJ, February 29, 2016―The Access Group (, a premier health care marketing communications agency, is proud to announce the launch today of its Oncology Business Unit. The creation of this unit was inspired by clients’ need for dedicated oncology expertise in an increasingly evolving and complex therapeutic space.

“As part of our commitment to delivering value for our clients, we continually strive to develop solutions that address their most pressing commercialization challenges and business needs,” said Jeff Gruenglas, Executive Vice President and lead for the Oncology Business Unit. “The creation of a dedicated oncology unit aggregates the decades of collective marketing and clinical practices of our accomplished team across solid tumors, hematologic malignancies, and genomics, including immunotherapies and companion diagnostics. This enables us to extend our clients’ access to novel approaches to insight discovery, industry experts, and truly measurable solutions.”


Strategic expertise to address industry challenges 

Oncology moves at the speed of science and research, giving rise to new challenges beyond the traditional framework. Today the business of treating cancer is shaped by policy, providers, payers, and patients. The demand for value in this complex environment creates the need for innovative paradigms and models that are commensurate with the dynamics of the oncology landscape. The new unit will augment the existing services offered by all Access Group entities by providing current and prospective biopharma and biotech clients with category intelligence, strategic initiatives, and therapy-specific content.

“Our clients are at the forefront of developing, commercializing, and helping patients get access to the therapies they need, and they do it well,” Gruenglas said. “Our goal is to be their oncology partner and help them reach their objectives with greater efficiencies and strategies, and to always deliver with value and outcomes that matter.”

“The Oncology Business Unit is a natural progression of the Access Group model of delivering value to our clients,” said Eric Bishea, company CEO. “The number of oncology initiatives from our client base has grown rapidly, resulting in our organization investing in and expanding our capabilities and resources. It is an exciting time to see so many new and promising compounds, and the Access Group is helping translate the value of these new developments in a way that will resonate with all stakeholders.”

The Oncology Business Unit is based out of the Access Group headquarters in New Jersey. To learn more about the unit, contact Jeff Gruenglas at or (908) 451-0623.

About the Access Group

The Access Group is the leading independent strategic health care communications network, composed of 5 distinct entities: Bioeclipse, Catalyst, FronTier Managed Markets, MedAccess, and Promidian—and 4 specialized service groups—S3, Strategic Selling Solutions; Government, Policy, Systems; the Oncology Business Unit, and StrataMed. The firm employs more than 130 health care marketing specialists, consultants, and senior leaders with experience in management consulting, brand promotion, marketing communications, managed markets, medical education, and training.

The Access Group is headquartered in Berkeley Heights, New Jersey, with offices in New York City, Chicago, San Diego, Los Angeles, and San Francisco. To learn more about the Access Group, please visit or contact Eric Bishea, CEO, at (908) 508-6700.

Media Contact: Kristen Supchak,